American Journal of Kidney Diseases
Volume 49, Issue 6 , Pages 732-735 , June 2007

In the Literature: Cancer Incidence Before and After Kidney Transplantation

  • Aparna Padiyar, MD
    • ,
  • Donald E. Hricik, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Donald E. Hricik, MD, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, Ohio, 44106 USA.

References 

  1. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89:1221–1227
  2. Hoshida Y, Tsukuma H, Yasunaga Y, et al. Cancer risk after renal transplantation in Japan. Int J Cancer. 1997;71:517–520
  3. Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet. 2000;355:1886–1887
  4. Kyollen L, Pukkala E, Eklund B. Cancer incidence in a kidney-transplanted population. Transpl Int. 1994;7(suppl 1):S350–S352
  5. Vajdic CM, McDonald SP, McCredie MRE, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823–2831
  6. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905–913
  7. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007;7:1–8
  8. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2003;4:222–230
  9. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004;4:87–93
  10. Opelz G, Naujokat C, Volker D, Terness P, Dohler Bernd. Dissociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81:1227–1233
  11. Meier-Kriesche HU, Chu AH, David KM, Chi-Burris K, Steffen BJ. Switching immunosuppression medications after renal transplantation—a common practice. Nephrol Dial Transplant. 2006;21:2256–2262
  12. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Med. 2002;8:128–135
  13. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 2003;63:914–926
  14. Koehl GE, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation. 2004;77:1319–1326
  15. Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation. 2005;80:749–758
  16. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80:883–889
  17. Kiberd BA, Keough-Ryan T, Clase CM. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant. 2003;3:619–625

 Support: None. Potential conflicts of interest: None.

PII: S0272-6386(07)00730-5

doi: 10.1053/j.ajkd.2007.04.007

American Journal of Kidney Diseases
Volume 49, Issue 6 , Pages 732-735 , June 2007

Article Tools

* Image Usage & Resolution